Elzonris Injection, Solution
NDC Package 72187-0401-1

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Frequently Asked Questions

Package Information

Elzonris (tagraxofusp) injection is eLZONRIS is a CD123-directed cytotoxin for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older. This formulation utilizes a injection, solution delivery system. Marketed by Stemline Therapeutics, Inc., this product is identified by NDC 72187-0401 and is authorized under FDA application BLA761116.

Identification & Billing

NDC Package Code
72187-0401-1
Package Description
1 VIAL, SINGLE-DOSE in 1 CARTON / 1 mL in 1 VIAL, SINGLE-DOSE
Product Code
72187-0401
11-Digit Billing Format
72187040101
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Elzonris
Non-Proprietary Name
Tagraxofusp
Substance Name
Tagraxofusp
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
TAGRAXOFUSP 1000 ug/mL
Pharmacologic Class
Usage Information
ELZONRIS is a CD123-directed cytotoxin for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older.

Regulatory & Marketing

Labeler Name
Stemline Therapeutics, Inc.
Product Type
Human Prescription Drug
FDA Application #
BLA761116
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
01-18-2019
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

J9269
Source: ASP
Inj. tagraxofusp-erzs 10 mcg
HCPCS Dosage 10 MCG
Units / Pkg 100

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 72187-0401-1 identifies a specific commercial package of 1 vial, single-dose in 1 carton / 1 ml in 1 vial, single-dose of Elzonris, a human prescription drug labeled by Stemline Therapeutics, Inc.. This injection, solution is formulated for intravenous use and contains tagraxofusp as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Stemline Therapeutics, Inc. on January 18, 2019. The current certification is valid through December 31, 2026.

How is this Stemline Therapeutics, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 72187040101. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
72187-0401-1
11-Digit CMS (5-4-2)
72187-0401-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.